Co-factors in HIV Mucosal Infection

HIV粘膜感染的辅助因素

基本信息

  • 批准号:
    7574447
  • 负责人:
  • 金额:
    $ 53.17万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-03-01 至 2013-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Worldwide, heterosexual transmission accounts for most HIV-1 infections. Clearly, controlling heterosexual transmission of HIV-1 would be a significant step toward eliminating this global epidemic. To achieve this goal, it will be important to delineate the cellular and molecular events that affect virus transmission. Although both inflammatory and ulcerative sexually transmitted infections (STIs) enhance sexual transmission of HIV-1, the underlying mechanisms leading to this enhancement have not been fully elucidated. Enhanced susceptibility to infection may be due to a number of factors, including the disruption of the integrity of the cervicovaginal epithelial barrier, recruitment of HIV-1 target cells such as Langerhans/dendritic cells (LC/DC), macrophages (M?) and T lymphocytes to sites of inflammation, and direct activation of target cells by STIs. A common feature of STI pathogens is that they encode ligands for members of the Toll-like receptor (TLR) family of pattern recognition receptors and these ligand-activated TLRs can both activate HIV-1 target cells and induce local inflammatory responses. Ligand-activated nuclear receptors (NR), including peroxisome proliferator activated receptor (PPAR), liver X receptor (LXR), glucocorticoid receptor (GR), are potent inhibitors of TLR-induced inflammatory gene expression in M?, LC/DC, and epithelial cells. In addition, retinoic acid receptor (RAR) and PPAR ligands have been shown to repress HIV-1 gene expression. Our initial goal is to determine the role of Neisseria gonorrhoeae exposure or TLR-signaling in augmenting HIV-1 infection of target cells that are found in the cervicovaginal mucosae. Our major and long-term goal is to examine the potential role of ligand-activated NR as inhibitors of HIV-1 transmission. We will test the hypothesis that ligand-activated NR act by: 1) directly repressing HIV-1 transcription, and 2) by limiting the STI or TLR-induced inflammatory microenvironment that favors HIV-1 replication. To achieve these goals, we will 1) evaluate the impact of NR/TLR crosstalk on HIV-1 replication and inflammatory gene expression in primary LC, DC, MF and T cells, 2) determine the mechanism(s) of TLR-modulated HIV-1 transcription and how it is regulated by NR signaling, and 3) examine the effects of NR/TLR crosstalk on HIV-1 infection of target cells and inflammation in vaginal and cervical tissue explants and in an organotypic model of the human vagina. PUBLIC HEALTH RELEVANCE: World-wide, most new infections with HIV-1, the virus that causes AIDS, occur in women who have had intercourse with infected men. The ability of HIV-1 to be transmitted to women is greater in those women who are also infected with other sexually transmitted diseases. This is partly due to the fact that these other diseases cause inflammation. We are studying a novel class of drugs that we believe inhibit HIV-1 infection by blocking both inflammation and the ability of HIV-1 to grow. We will test these drugs for their ability to inhibit HIV-1 transmission using purified cells and a unique laboratory-derived tissue model of the female reproductive tract.
描述(由申请人提供):在世界范围内,异性传播占大多数HIV-1感染。显然,控制HIV-1的异性传播将是消除这一全球流行病的重要一步。为了实现这一目标,它将是重要的是描绘的细胞和分子的事件,影响病毒的传播。虽然炎症性和溃疡性传播感染(STI)增强了HIV-1的性传播,但导致这种增强的潜在机制尚未完全阐明。感染易感性增强可能是由于许多因素,包括宫颈阴道上皮屏障完整性的破坏,HIV-1靶细胞如朗格汉斯/树突状细胞(LC/DC)、巨噬细胞(M?)和T淋巴细胞到炎症部位,并通过STI直接激活靶细胞。STI病原体的一个共同特征是它们编码模式识别受体的Toll样受体(TLR)家族成员的配体,并且这些配体激活的TLR可以激活HIV-1靶细胞并诱导局部炎症反应。配体激活的核受体(NR),包括过氧化物酶体增殖物激活受体(PPAR)、肝X受体(LXR)、糖皮质激素受体(GR),是TLR诱导的M?炎症基因表达的有效抑制剂,LC/DC和上皮细胞。此外,视黄酸受体(RAR)和过氧化物酶体增殖物激活受体配体已被证明抑制HIV-1基因的表达。我们最初的目标是确定淋病奈瑟菌暴露或TLR信号在增强宫颈阴道粘膜中发现的靶细胞的HIV-1感染中的作用。我们的主要和长期目标是研究配体激活的NR作为HIV-1传播抑制剂的潜在作用。我们将检验配体激活的NR通过以下方式发挥作用的假设:1)直接抑制HIV-1转录,2)限制STI或TLR诱导的有利于HIV-1复制的炎症微环境。为了实现这些目标,我们将1)评估NR/TLR串扰对原代LC、DC、MF和T细胞中HIV-1复制和炎性基因表达的影响,2)确定TLR调节的HIV-1转录的机制以及NR信号传导如何调节HIV-1转录,和3)检查NR/TLR串扰对HIV-1的影响。1阴道和宫颈组织外植体中以及人阴道器官型模型中靶细胞的感染和炎症。 公共卫生关系:在世界范围内,大多数新感染HIV-1(导致艾滋病的病毒)的妇女都与受感染的男子发生过性关系。艾滋病毒-1在那些同时感染其他性传播疾病的妇女中传播给妇女的能力更大。这部分是由于这些其他疾病引起炎症的事实。我们正在研究一种新型药物,我们认为这种药物可以通过阻断炎症和HIV-1的生长能力来抑制HIV-1感染。我们将使用纯化的细胞和一种独特的实验室来源的女性生殖道组织模型来测试这些药物抑制HIV-1传播的能力。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GREGORY A. VIGLIANTI其他文献

GREGORY A. VIGLIANTI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GREGORY A. VIGLIANTI', 18)}}的其他基金

REAGENT / VECTOR CORE
试剂/载体核心
  • 批准号:
    8504904
  • 财政年份:
    2013
  • 资助金额:
    $ 53.17万
  • 项目类别:
REAGENT / VECTOR CORE
试剂/载体核心
  • 批准号:
    8290054
  • 财政年份:
    2011
  • 资助金额:
    $ 53.17万
  • 项目类别:
REAGENT / VECTOR CORE
试剂/载体核心
  • 批准号:
    8120847
  • 财政年份:
    2010
  • 资助金额:
    $ 53.17万
  • 项目类别:
Co-factors in HIV Mucosal Infection
HIV粘膜感染的辅助因素
  • 批准号:
    7771771
  • 财政年份:
    2008
  • 资助金额:
    $ 53.17万
  • 项目类别:
Co-factors in HIV Mucosal Infection
HIV粘膜感染的辅助因素
  • 批准号:
    8025980
  • 财政年份:
    2008
  • 资助金额:
    $ 53.17万
  • 项目类别:
Co-factors in HIV Mucosal Infection
HIV粘膜感染的辅助因素
  • 批准号:
    7494345
  • 财政年份:
    2008
  • 资助金额:
    $ 53.17万
  • 项目类别:
Co-factors in HIV Mucosal Infection
HIV粘膜感染的辅助因素
  • 批准号:
    8225118
  • 财政年份:
    2008
  • 资助金额:
    $ 53.17万
  • 项目类别:
Retinoid Repression of HIV Through Chromatin Remodeling
类视黄醇通过染色质重塑抑制 HIV
  • 批准号:
    6746875
  • 财政年份:
    2001
  • 资助金额:
    $ 53.17万
  • 项目类别:
Retinoid Repression of HIV Through Chromatin Remodeling
类视黄醇通过染色质重塑抑制 HIV
  • 批准号:
    6632387
  • 财政年份:
    2001
  • 资助金额:
    $ 53.17万
  • 项目类别:
Retinoid Repression of HIV Through Chromatin Remodeling
类视黄醇通过染色质重塑抑制 HIV
  • 批准号:
    6511438
  • 财政年份:
    2001
  • 资助金额:
    $ 53.17万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 53.17万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 53.17万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 53.17万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 53.17万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 53.17万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 53.17万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 53.17万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 53.17万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 53.17万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 53.17万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了